-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 17, Eli Lilly and Company and Boehringer Ingelheim jointly announced that the SGLT2 inhibitor empagliflozin for the treatment of chronic kidney disease (CKD) patients was based on the recommendation of an independent data monitoring committee.
CKD is a serious disease of decreased kidney function that affects nearly 850 million people worldwide, and many patients go undiagnosed
Empagliflozin is a once-daily, highly selective inhibitor of sodium-glucose co-transporter 2 (SGLT2) that prevents sugar from being reabsorbed by the kidneys in patients with type 2 diabetes with high blood sugar levels.
References:
[1] Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease.
(Original abridged)